If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 231 - 240 of 279
A Phase 1b/2, Multicenter, Open-Label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-Line Induction or Maintenance, in Subjects with Extensive-Stage
Objective
A Phase 1b 2 Study of I-DXd, ADC, in Combination in Patients with ES-SCLC
Protocol No
DAIICHI-SANKYO-DS7300-189
Categories
A Phase 2 Multi-cohort, Open-label, Multi-center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone and in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Metastatic Urothelial Car
Objective
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Protocol No
SEAGEN-RC48G001
Categories
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Post-Approval Study
Objective
GORE TAMBE Post-Approval Study
Protocol No
SURG-WLGORE-TAMBE
Categories
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Objective
A Phase 1/2 Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Protocol No
MIRATI-1719-001
Categories
Cancer,
Other Skin,
Thoracic Cancers,
Gynecologic Cancers,
Other Gastrointestinal,
Early Phase/Multiple Disease Site Cancers,
Lip, Oral Cavity and Pharynx,
Melanoma, Skin,
Esophagus,
Bladder,
Pancreas/Liver,
Prostate,
Skin Cancers,
Kidney,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Colorectal,
Gastrointestinal Cancers,
Sarcoma,
Breast Cancers
A Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-Cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or
Objective
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Protocol No
LEGEND-LB1908-1001-GI
Categories
A Randomized Controlled Phase 2 Study of the Ketogenic Diet Versus Standard Dietary Guidance for Patients with Newly Diagnosed Glioblastoma in Combination with Standard-of-Care Treatment
Objective
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
Protocol No
CEDAR-IIT2022-06-HU-DIET2TREAT
Categories
CureAA: Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia - A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, o
Objective
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
Protocol No
HEMONC-CTN-2207-CUREAA
Categories
Concept Representation in the Human Brain
Objective
Concept Representation in the Human Brain
Protocol No
NEURO-NIH-CONCEPT-REP-BRAIN
A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial
Objective
Comparing cytarabine + daunorubicin therapy versus cytarabine + daunorubicin + venetoclax versus venetoclax + azacitidine in younger patients with intermediate risk AML
Protocol No
CCTG-MM1YA-CTG01
Categories
A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma
Objective
Trial of Zanubrutinib in older patients with mantle cell lymphoma
Protocol No
ALLIANCE-A052101
Categories